Search Results
Dec 08, 2025, 08:03 ET Grace and Molecule.one to Transform Peptide Building Block Synthesis with AI and Automation
strengthen U.S. manufacturing capabilities and help bring lifesaving medicines to patients fasterCOLUMBIA, Md. and WARSAW, Poland, Dec. 8, 2025 /PRNewswire/ --
More news about: W. R. Grace
Dec 08, 2025, 08:00 ET Astrin Biosciences Announces Scientific Advisory Board to Advance Early Cancer Detection Leveraging AI and Proteomics
Barbara Levy, MD, FACOG, FACS, MSCP, Chief Medical Officer at Visana Health, Clinical Professor at George Washington University and UC San Diego Health, and the
More news about: Astrin Biosciences
Dec 08, 2025, 08:00 ET EyeYon Medical Ltd. Receives FDA IDE Approval to Initiate U.S. Clinical Study of EndoArt®, the First Artificial Endothelial Layer for Corneal Edema
The study will be led by Professor Francis Mah, MD, Director of Cornea and External Disease, Scripps Clinic Medical Group. The clinical investigation will include at least 10 leading U.S. cornea surgeons
More news about: EyeYon Medical
Dec 08, 2025, 07:30 ET Recordati Rare Diseases Showcases Real-World Evidence Studies That Advance Understanding of Castleman Disease (CD) at the American Society of Hematology (ASH) Annual Meeting
understanding of rare hematologic disorders, as exemplified by our continued support of research in Castleman disease," said Alessandro Albuquerque, MD, PhD, Chief Medical Officer and Vice President of Medical Affairs and Clinical Development at Recordati. "We are proud to work with esteemed research
More news about: Recordati
Dec 08, 2025, 07:30 ET Contango ORE and Dolly Varden Silver Announce Merger to Create a New North American High-Grade, Mid-Tier Silver & Gold Producer and Developer
expectations; and other risks described from time to time in Dolly Varden's most recently filed annual information form, financial statements and, MD&A and other disclosures (under the heading "Risk Factors" or otherwise) which are available on SEDAR+ at www.sedarplus.ca
More news about: Contango Ore
Dec 08, 2025, 07:00 ET VERSABANK CONGRATULATES RPP PARTNER ECN CAPITAL ON PRIVATIZATION TRANSACTION
the risks implicated by the foregoing. For a detailed discussion of certain key factors that may affect our future results, please see our annual MD&A for the year ended October 31, 2024.The foregoing list of important factors is not exhaustive. When relying on forward-looking statements to
More news about: VersaBank
Dec 08, 2025, 06:00 ET AFP Partners with PwC Academy Dubai on Exam Preparation Courses for the CTP Certification
Partnership provides access to in-person courses in Dubai for the leading treasury credentialROCKVILLE, Md., Dec. 8, 2025 /PRNewswire/ -- The Association for Financial Professionals (AFP) announced a new partnership with
More news about: Association for Financial Professionals
Dec 08, 2025, 06:00 ET Realtor.com® Monthly Housing Report: Affordability Reshapes Where Americans Can Buy Homes
1.6Baltimore-Columbia-Towson, MD22.8 %
More news about: Realtor.com
Dec 08, 2025, 05:00 ET Allison Worldwide Expands Global Leadership with New Europe CEO
Former Hotwire UK CEO and Edelman MD Jeremy Lucas to turbocharge Allison's European capabilitiesLONDON, Dec. 8, 2025 /PRNewswire/ -- Allison Worldwide, part of Stagwell (STGW), has announced the
More news about: Stagwell Inc.
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry
More news about: Innovent Biologics
Dec 07, 2025, 12:01 ET Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
gene therapy, providing clear, long-term data of the ability of HEMGENIX to potentially transform care for adults with hemophilia B," said Steven Pipe, MD, Professor of Pediatrics and Pathology, Hemophilia and Coagulation Disorders Program and the Special Coagulation Laboratory, University of Michigan. "For
More news about: CSL
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
non-inferior to ibrutinib, and the response rate actually favors pirtobrutinib in the total cohort," said lead study author Jennifer Woyach, MD, Bertha Bouroncle, MD, and Andrew Pereny, chair of medicine at The Ohio State University College of Medicine. "This shows that pirtobrutinib is a reasonable choice
More news about: American Society of Hematology
Dec 06, 2025, 22:40 ET Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry
More news about: Innovent Biologics
Dec 06, 2025, 15:40 ET Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC
for patients with NRG1-positive NSCLC, a patient population that typically responds poorly to standard first-line therapy," said Stephen Liu, MD, of Georgetown University. "Early and durable responses, coupled with a favorable safety profile are encouraging and highlight the importance of targeted
More news about: Partner Therapeutics, Inc.
Dec 06, 2025, 08:30 ET Advances in Technology Help Improve Safety and Access to Blood Cancer Therapies
together different approaches bringing technological improvements to bear on therapeutic innovation and improving patient safety," said Wendy Stock, MD, Anjuli Seth Nayak Professor of Medicine at the University of Chicago Medicine, who moderated the press briefing The Next Wave of Innovation: Breakthrough
More news about: American Society of Hematology
Dec 06, 2025, 07:15 ET Studies Highlight Innovative Approaches to Improving Patient Care and Outcomes
on this study (Puja Umaretiya, MD, and Kira Bona, MD, MPH) are leading clinical trials examining whether benefits counseling and cash payments reduce financial hardship among low-income families whose children are receiving cancer treatment.Daniel Zheng, MD, of Children's Hospital of Philadelphia,
More news about: American Society of Hematology
Dec 06, 2025, 07:00 ET Research Reveals Avenues for Informing and Improving Sickle Cell Care
accountable to our patients in terms of care and pain management, and to give context about the next phase of sickle cell therapies," said Titilope Fasipe, MD, PhD, associate professor of pediatrics at Baylor College of Medicine and co-director of the sickle cell and thalassemia program at Texas Children's
More news about: American Society of Hematology
Dec 05, 2025, 17:45 ET AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
neurofilament biomarker changes aligned with clinical benefit."We are very excited by the positive Phase 2 results for AP-101," said Angela Genge, MD, Chief Medical Officer of AL-S Pharma. "We are observing very consistent results across survival, function, and biomarkers in two independent cohorts
More news about: AL-S Pharma AG
Dec 05, 2025, 14:37 ET Salt Lake City Oculoplastic Surgeon Dr. Kian Eftekhari to Present Innovative Ptosis Technique at International ABAM Conference
www.eyelidcenterutah.com or call 801-685-3398.Media ContactKian Eftekhari, MDEyelid Center of Utah801-685-3398
More news about: Eyelid Center of Utah
Dec 05, 2025, 12:46 ET Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
discuss the latest research on emapalumab, efanesoctocog alfa, pegcetacoplan, avatrombopag, as well as loncastuximab tesirine," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi.Summary of full Sobi data to be presented at ASH 2025:Overview
More news about: Swedish Orphan Biovitrum AB
Dec 05, 2025, 12:39 ET American Nurses Association Reaffirms Support for Evidence-Based Immunizations Following CDC Panel Vote on Hepatitis B Vaccine
Decision-Making and Policies that Protect the Health of Infants, Families, and CommunitiesSILVER SPRING, Md., Dec. 5, 2025 /PRNewswire/ -- The American Nurses Association (ANA) reaffirms its strong support for immunizations
More news about: American Nurses Association
Dec 05, 2025, 12:00 ET AAOS Establishes Orthobiologics Registry to Advance Evidence-Based Orthobiologics Research
orthobiologics continue to grow in popularity, we're at a critical juncture where we need facts, not fiction, about their effectiveness," said Jason Dragoo, MD, FAAOS, chair of the AAOS OBR and AAOS Committee on Devices, Biologics and Technology. "This registry will help us understand which patients benefit most
More news about: American Academy of Orthopaedic Surgeons
Dec 05, 2025, 11:13 ET New Energy Equity's Lift As We Climb Foundation Raises $143,000 for Let's Share the Sun Foundation at 4th Annual Charity Golf Tournament
ANNAPOLIS, Md., Dec. 5, 2025 /PRNewswire/ -- New Energy Equity and its Lift As We Climb Foundation (LAWC) raised $143,000 to support Let's Share the Sun Foundation (LSTS), a nonprofit dedicated to bringing solar energy to underserved
More news about: New Energy Equity
Dec 05, 2025, 10:45 ET Ceva-XC21 Named "Best IP/Processor of the Year" at EE Awards Asia
with ultra-efficient, AI-enabled DSP architecture for cost-sensitive IoT and smart-home devicesROCKVILLE, Md., Dec. 5, 2025 /PRNewswire/ -- Ceva, Inc. (NASDAQ: CEVA), the leading licensor of silicon and software IP for
More news about: Ceva, Inc.
Dec 05, 2025, 10:00 ET Preliminary Data from FANSS Study Show Potential for Blood-Based Lung Cancer Detection in Non-Smoking Population
enrolled 1,000 participants who underwent baseline LDCT, and 13 were diagnosed with invasive lung adenocarcinoma, a 1.3% detection rate," said Elaine Shum, MD, an oncologist and assistant professor at NYU Grossman School of Medicine, and the study's lead investigator. "This rate is higher than what was observed
More news about: DELFI Diagnostics